SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: jopawa who wrote (2238)6/30/1999 10:47:00 AM
From: David Winkler  Respond to of 2539
 
I suppose that nobody that takes vioxx will ever die. What a fluff piece of sh__ for merck!!

"Celebrex also may have been hurt by reports of some deaths among
patients taking it. There is no clear causality established, and the Food
and Drug Administration is confident that Celebrex is safe. Concerns
are around, however. "



To: jopawa who wrote (2238)7/1/1999 2:24:00 PM
From: John F Beule  Read Replies (3) | Respond to of 2539
 
Any thoughts on selling of sweetner biz, and new CEO?



To: jopawa who wrote (2238)7/1/1999 7:07:00 PM
From: Anthony Wong  Respond to of 2539
 
Monsanto Co. Maintained 'Buy' at Salomon Smith Barney

Bloomberg News
July 1, 1999, 4:04 p.m. ET

Princeton, New Jersey, July 1 (Bloomberg Data) -- Monsanto Co. (MTC US)
was maintained ''buy'' by analyst James H. Wilbur at Salomon Smith Barney.
The 12-month target price is $55.00 per share.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News